IRIS
FAVOINO, ELVIRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.378
EU - Europa 2.340
AS - Asia 1.921
SA - Sud America 505
AF - Africa 89
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
Totale 9.238
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.303
RU - Federazione Russa 830
SG - Singapore 756
IT - Italia 696
CN - Cina 450
BR - Brasile 405
HK - Hong Kong 252
SE - Svezia 218
VN - Vietnam 153
DE - Germania 126
FR - Francia 119
FI - Finlandia 91
GB - Regno Unito 81
UA - Ucraina 79
IN - India 61
BD - Bangladesh 51
AR - Argentina 37
ID - Indonesia 36
TR - Turchia 31
CA - Canada 28
MX - Messico 22
PL - Polonia 20
ZA - Sudafrica 20
CI - Costa d'Avorio 18
JP - Giappone 17
NL - Olanda 17
IQ - Iraq 16
CO - Colombia 15
AT - Austria 14
BE - Belgio 14
PK - Pakistan 13
UZ - Uzbekistan 13
MY - Malesia 12
CL - Cile 11
EC - Ecuador 11
TN - Tunisia 10
ES - Italia 9
DZ - Algeria 8
PH - Filippine 8
PY - Paraguay 7
SA - Arabia Saudita 7
VE - Venezuela 7
EG - Egitto 6
IE - Irlanda 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
CR - Costa Rica 5
JO - Giordania 5
PE - Perù 5
TH - Thailandia 5
UY - Uruguay 5
DO - Repubblica Dominicana 4
KE - Kenya 4
LT - Lituania 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
HR - Croazia 3
IL - Israele 3
PA - Panama 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AO - Angola 2
BB - Barbados 2
BO - Bolivia 2
BW - Botswana 2
CG - Congo 2
EE - Estonia 2
GE - Georgia 2
JM - Giamaica 2
KR - Corea 2
LB - Libano 2
NP - Nepal 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SV - El Salvador 2
ZW - Zimbabwe 2
AM - Armenia 1
AU - Australia 1
BF - Burkina Faso 1
BH - Bahrain 1
BZ - Belize 1
CH - Svizzera 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GH - Ghana 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
ML - Mali 1
MM - Myanmar 1
NG - Nigeria 1
PT - Portogallo 1
QA - Qatar 1
Totale 9.232
Salva come PNG Salva come JPEG
Città #
Ashburn 445
Fairfield 421
Singapore 382
Chandler 311
Woodbridge 263
Houston 253
Hong Kong 251
Milan 213
Bari 211
Jacksonville 209
San Jose 209
Ann Arbor 189
Nyköping 186
Cambridge 184
Seattle 180
Wilmington 167
Beijing 137
Rome 88
Nanjing 72
Lauterbourg 69
New York 65
Roxbury 63
Lawrence 60
Boardman 59
Los Angeles 49
Dallas 47
Des Moines 42
Ho Chi Minh City 42
Princeton 36
Helsinki 34
Inglewood 34
Columbus 29
Hanoi 29
Moscow 27
Santa Clara 27
São Paulo 24
Dearborn 23
Buffalo 22
Jakarta 21
London 21
Pune 20
Brooklyn 19
Falkenstein 19
Shenyang 19
Abidjan 18
Council Bluffs 18
Orem 18
Warsaw 18
San Diego 17
Tokyo 17
Frankfurt am Main 16
Munich 16
Paris 16
Turin 16
Chicago 15
Belo Horizonte 14
Dong Ket 14
Rio de Janeiro 14
Brussels 13
Haiphong 13
Montreal 13
Noicattaro 13
Tashkent 13
Atlanta 11
Chennai 11
Figino 11
Guangzhou 11
Nanchang 11
Amsterdam 10
Nuremberg 10
San Francisco 10
Tianjin 10
Boston 9
Hebei 9
The Dalles 9
Ankara 8
Johannesburg 8
Mexico City 8
Vienna 8
Changsha 7
Denver 7
Poplar 7
Shanghai 7
Stockholm 7
Dublin 6
Fortaleza 6
Indiana 6
Jiaxing 6
Kuala Lumpur 6
Medellín 6
Toronto 6
Washington 6
Auburn Hills 5
Bologna 5
Brasília 5
Buenos Aires 5
Campinas 5
Cape Town 5
Curitiba 5
Dhaka 5
Totale 5.840
Salva come PNG Salva come JPEG
Nome #
Response to "Is active acid sphingomyelinase required for the antiproliferative response to rituximab?" [e-letter]. http://bloodjournal.hematologylibrary.org/content/117/13/3695.citation/reply#bloodjournal_el_2268 766
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 223
ANTIBODIES TO ENDOPLASMIN AND THEIR USE 200
CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading 198
Methods for treating a tumor using an antibody that specifically binds HMW-MAA 196
Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis 187
Autoantibodies Recognizing the Amino Terminal 1-17 Segment of CENP-A Display Unique Specificities in Systemic Sclerosis 179
Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin 178
Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study 169
CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases 167
Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. 161
AB0695 Subspecificities of Anti-Centromeric-Associated Protein a (CENP-A) Antibodies (AB) Can Identified a Subset of Patients at Higher Risk of Developing Pulmonary Hypertension 158
Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease 154
Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis 150
CD20 mimicry by a mAb rituximab-specific linear peptide: A potential tool for active immunotherapy of autoimmune diseases 150
Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart? 145
Rheumatic disorders as paraneoplastic syndromes 142
CD20: A target antigen for immunotherapy of autoimmune diseases 137
Effects of Adjuvants for Human Use in Systemic Lupus Erythematosus (Sle)-Prone (Nzb/Nzw) F1 Mice 135
Abstract 4390: Heat shock protein (HSP) Grp94-targeted combinatorial immunotherapy for pancreatic cancer 133
Anti-carbamylated protein antibodies in patients with systemic sclerosis: an intriguing association with skin involvement 130
The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells 129
Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease 128
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor 126
CD20 mimicry by mAb Rituximab-specific linear peptide. A potential tool for active immunotherapy of autoimmune diseases 126
Identification of an antigenic and immunogenic motif expressed by two 7-Mer Rituximab-specific cyclic peptides 124
Dietary cholesterol supplementation and inhibitory factor 1 serum levels in two dizygotic Smith-Lemli-Opitz syndrome twins: a case report 120
Antitumor activity of BRAF inhibitor and IFN×alpha; Combination in BRAF-mutant melanoma 119
Novel combinatorial therapy for pancreatic adenocarcinoma 118
Circulating Irisin Levels in Patients with Chronic Plaque Psoriasis. 117
Beta2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide 117
SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? 117
Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes 115
Sars-cov-2 inflammatory syndrome. Clinical features and rationale for immunological treatment 114
HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors 113
Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: Putative implication of a low anti-carbamylated protein antibodies prevalence 112
CSPG4 in cancer: Multiple roles 111
Endothelial cells in tumor microenvironment: insights and perspectives 107
HLA allele prevalence in disease-modifying antirheumatic drugs-responsive enthesitis and/or arthritis not fulfilling ASAS criteria: Comparison with psoriatic and undifferentiated spondyloarthritis 104
Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: Implication for peptide-based active immunotherapy 104
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count 103
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence 103
Characterization of the specificity of the Human scFv W9 101
Circulating Inhibitory Factor 1 levels in adult patients with Prader-Willi syndrome 101
Identificazione del peptide che mima l'epitopo localizzato sulla catena pesante HLA-I non associata alla beta 2-microglobulina, riconosciuto dall'anticorpo monoclonale HC-10 100
Targeting cancer initiating cells in pancreatic adenocarcinoma 95
Harnessing host innate immunity may combat acquired resistance to BRAFi 94
Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4 94
Raynaud’s phenomenon: from molecular pathogenesis to therapy 92
EXPRESSION OF THE TRANSCRIPTION FACTOR FORKHEAD BOX E3 (FOXE3) IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH SYSTEMIC SCLEROSIS 88
EXPRESSION OF THE TRANSCRIPTION FACTOR FORKHEAD BOX E3 (FOXE3) IN MONOCYTES FROM PATIENTS WITH SYSTEMIC SCLEROSIS AND CORRELATION WITH THEIR SEROLOGICAL PROFILE 87
Insight into the specificità of the anti-CD20 monclonal antibody Rituximab. 87
AUTO-ANTIBODIES TO THE AMINO TERMINAL SEGMENT (AMINOACID 1-17) OF CENP-A DISPLAY A UNIQUE SPECIFICITY IN SYSTEMIC SCLEROSIS AND ARE INDEPENDENTLY EXPRESSED FROM THOSE AGAINST CENP-B 87
Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope 86
Metodo ELISA: dosaggio della catena pesante della molecola HLA non associata alla b2-microglobulina 84
Ruolo degli autoanticorpi nelle patologie autoimmuni 83
Phlegmonous abscess associated with etanercept therapy 78
Idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH): Similarities, differences and the role of autoimmunity 78
Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity 77
null 77
Chronic-Relapsing cutaneous leukocytoclastic vasculitis in a young patient with reduced EBV-specific T cell response using enzyme-linked immunospot (ELISPOT) assay successfully treated with Valaciclovir 77
Peptidi che mimano l'antigene CD20: potenzialità terapeutiche nel lupus eritematoso sistemico 74
Poems syndrome with amyloidosis and calchyphylaxis.A case report 73
Ruolo degli autoanticorpi nelle patologie autoimmuni 72
Functional characterization of peptides mimicking the CD20 epitope recognized by Rituximab 70
Identification of an antigenic and immunogenic motif expressed by two 7-Mer Rituximab-specific cyclic peptides. Journal of Immunology 70
Why Do We Still Lack a COVID-19 Vaccine? Searching for the Missing Pieces 69
Two structurally different peptides mimic a CD20 epitope recognized by rituximab 68
Quantitative evaluation of anti-FOXE-3 Ab identifies a subset of anti-CENP positive systemic sclerosis patients who are less prone to develop active disease 67
Impact of belimumab therapy on the quality of life in patients with systemic lupus erythematosus: A cohort study 66
Generation of linear and cyclic peptides revealed a unique fine specificity of Rituximab and its possible cross-reactivity with an acid sphingomyelinase-like phosphodiesterasem 3B precursor 66
 Peptides highly specific to the variable region of TNF-ALFA-specific references licensed (RL) monoclonal antibodies (MAB), as potential tool to effectively assess similarity between biosimilars and the correspondig RL MAB 65
Novel biomarker for pulmonary vascular disease in systemic sclerosis patients 63
Mimotope peptides in the immunization against CD20: a promising approach to the therapy of autoimmune diseases 57
Classic pyoderma gangrenosum 50
null 49
Clinical and subclinical atherosclerosis in patients with systemic sclerosis: an observational, multicentre study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 48
Primary versus systemic-sclerosis-associated Raynaud's phenomenon: relationship with clinical and environmental factors 48
Methods for treating a tumor using an antibody that specifically binds grp94 44
Clinical correlates of a subset of anti-fibroblast antibodies in systemic sclerosis 37
null 33
β2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide 33
Functional characterization of peptides mimicking the CD-20 epitope recognized by Rituximab 30
Type II diabetes in systemic sclerosis patients: insights from an observational, multicenter study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 27
Barriers to therapy adherence in a group of Italian patients with systemic lupus erythematosus 27
Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAFV600E melanoma 23
Novel Biomarker for Antimitochondrial Antibodies in Systemic Sclerosis Patients 7
Clinical associations and related factors of metabolic syndrome in systemic sclerosis: results from an observational multicenter study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 5
Inflammatory biomarkers of atherosclerosis in SLE that may improve SLE-specific cardiovascular risk assessment tools 5
Totale 9.497
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.802
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.802
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022522 24 67 6 18 22 34 51 22 32 23 97 126
2022/2023844 122 94 45 74 107 105 29 116 113 9 16 14
2023/2024363 24 53 19 70 21 77 11 21 8 8 6 45
2024/20251.280 79 18 114 20 28 86 158 106 53 67 178 373
2025/20263.707 396 159 181 374 307 170 354 93 934 255 82 402
2026/2027100 100 0 0 0 0 0 0 0 0 0 0 0
Totale 9.497